[go: up one dir, main page]

MX2020014031A - Proteinas heterodimericas y usos de las mismas. - Google Patents

Proteinas heterodimericas y usos de las mismas.

Info

Publication number
MX2020014031A
MX2020014031A MX2020014031A MX2020014031A MX2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A
Authority
MX
Mexico
Prior art keywords
heterodimeric proteins
proteins
immunotherapies
autoimmunity
cancer
Prior art date
Application number
MX2020014031A
Other languages
English (en)
Inventor
George Fromm
Taylor Schreiber
Silva Suresh De
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of MX2020014031A publication Critical patent/MX2020014031A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere, entre otros, a composiciones y métodos, incluyendo proteínas heterodiméricas que encuentran uso en el tratamiento de enfermedades, tales como inmunoterapias para el cáncer y autoinmunidad.
MX2020014031A 2018-06-21 2019-06-21 Proteinas heterodimericas y usos de las mismas. MX2020014031A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688167P 2018-06-21 2018-06-21
US201862703248P 2018-07-25 2018-07-25
PCT/US2019/038451 WO2019246508A1 (en) 2018-06-21 2019-06-21 Heterodimeric proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2020014031A true MX2020014031A (es) 2021-05-12

Family

ID=68983045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014031A MX2020014031A (es) 2018-06-21 2019-06-21 Proteinas heterodimericas y usos de las mismas.

Country Status (10)

Country Link
US (3) US10995127B2 (es)
EP (1) EP3810172A4 (es)
JP (3) JP7439372B2 (es)
KR (1) KR20210025054A (es)
CN (1) CN112566650A (es)
AU (1) AU2019290192A1 (es)
BR (1) BR112020026112A2 (es)
CA (1) CA3103975A1 (es)
MX (1) MX2020014031A (es)
WO (1) WO2019246508A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020014031A (es) * 2018-06-21 2021-05-12 Shattuck Labs Inc Proteinas heterodimericas y usos de las mismas.
WO2021041958A1 (en) * 2019-08-30 2021-03-04 Shattuck Labs. Inc. Chimeric proteins in autoimmunity
WO2021202354A1 (en) * 2020-03-30 2021-10-07 Proviva Therapeutics (Hong Kong) Limited Il-2/il-15 compositions and methods of use thereof
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
IL308087A (en) 2021-05-12 2023-12-01 Applied Biomedical Science Inst Methods for the screening and expression of disulfide-bonded polypeptides
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
EP4511054A2 (en) * 2022-04-20 2025-02-26 Neptune Biosciences LLC Orthogonal il-21 receptor/cytokine systems
WO2023225488A1 (en) 2022-05-16 2023-11-23 Enkefalos Biosciences, Inc. Blood-brain barrier translocating peptides and related molecules and methods of use thereof
WO2024019984A1 (en) * 2022-07-18 2024-01-25 Cargo Therapeutics, Inc. Cytokine receptor switch polypeptides and uses thereof
WO2024108050A1 (en) 2022-11-16 2024-05-23 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2025133115A1 (en) * 2023-12-21 2025-06-26 Ose Immunotherapeutics Lipid-based nanoparticles comprising il-35
WO2025140436A1 (zh) * 2023-12-27 2025-07-03 上海药明生物技术有限公司 重组il-27蛋白及其制备方法
CN117986386B (zh) * 2024-02-06 2024-11-29 康立泰生物医药(青岛)有限公司 重组人白细胞介素-35及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69518838T2 (de) * 1994-05-18 2001-05-03 The Protein Engineering Network Of Centres Of Excellence (Pence), Inc. Heterodimere trägerzusammensetzung von immunogenen polypeptiden und verfahren zu deren verwendung
IT1274350B (it) * 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
US6193972B1 (en) * 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. Hybrid heterodimeric protein hormone
DK1037927T3 (da) * 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
PL202058B1 (pl) * 1999-08-09 2009-05-29 Merck Patent Gmbh Wielofunkcyjne białko fuzyjne cytokin i przeciwciała
WO2002012345A2 (en) * 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
ES2360862T3 (es) * 2004-07-09 2011-06-09 Variety Children's Hospital D/B/A/ Miami Children's Hospital Materiales y procedimientos para la estimulación del sistema inmunitario.
EP2072527A1 (en) * 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
CA2781519A1 (en) * 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
HUE029257T2 (en) * 2009-12-29 2017-02-28 Aptevo Res And Dev Llc Heterodimer binding proteins and their use
US10706955B2 (en) * 2010-03-23 2020-07-07 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CN111138543B (zh) * 2013-03-15 2024-06-11 Xencor股份有限公司 异二聚体蛋白
US10017545B2 (en) * 2013-06-03 2018-07-10 University Of Maryland, College Park Compositions and vaccines comprising vesicles and methods of using the same
BR112017004953A2 (pt) * 2014-09-17 2017-12-05 Genentech Inc imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
WO2016141357A1 (en) * 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
CA2991259A1 (en) * 2015-07-26 2017-02-02 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
SG10201913573UA (en) * 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
CR20180318A (es) * 2015-12-14 2018-09-19 Macrogenics Inc Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
US10906957B2 (en) * 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
US12447213B2 (en) * 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
MY207687A (en) * 2017-02-27 2025-03-12 Shattuck Labs Inc Tigit- and light-based chimeric proteins
MX2020014031A (es) * 2018-06-21 2021-05-12 Shattuck Labs Inc Proteinas heterodimericas y usos de las mismas.
US11098093B2 (en) * 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
WO2021041958A1 (en) * 2019-08-30 2021-03-04 Shattuck Labs. Inc. Chimeric proteins in autoimmunity

Also Published As

Publication number Publication date
AU2019290192A1 (en) 2021-01-07
US10995127B2 (en) 2021-05-04
EP3810172A4 (en) 2022-04-20
WO2019246508A1 (en) 2019-12-26
JP7452932B2 (ja) 2024-03-19
KR20210025054A (ko) 2021-03-08
BR112020026112A2 (pt) 2021-04-06
EP3810172A1 (en) 2021-04-28
JP7439372B2 (ja) 2024-02-28
JP2021527700A (ja) 2021-10-14
CA3103975A1 (en) 2019-12-26
JP2024057087A (ja) 2024-04-23
CN112566650A (zh) 2021-03-26
JP2023116718A (ja) 2023-08-22
US11780897B2 (en) 2023-10-10
US20230220030A1 (en) 2023-07-13
US20210214409A1 (en) 2021-07-15
US20200079831A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
ZA201905488B (en) Tigit- and light-based chimeric proteins
PH12018500694A1 (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
MY203971A (en) Anti-lag-3 antibodies and compositions
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
WO2018190719A3 (en) Anti-sirp alpha antibodies
MX2022007140A (es) Terapias combinadas dirigidas a proteina 1 de muerte celular programada (pd-1), proteina 3 de dominio de mucina y dominio inmunoglobulina de los linfocitos t (tim-3), y gen de activacion de linfocitos 3 (lag-3).
CL2018003582A1 (es) Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567)
CR20200114A (es) Compuestos que contienen pirazolopirimidinona y sus usos
PH12020550051A1 (en) Glp-1 compositions and uses thereof
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
PH12016501107A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MY197534A (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
PH12021551475A1 (en) Heterodimeric proteins for modulating gamma delta t cells
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2021002286A (es) Terapias de combinacion.
MX2024005649A (es) Proteinas quimericas basadas en sirp1a y cd40l.